AR042024A1 - Compuestos farmaceuticos derivados de piridona, pirimidona y pirazinona - Google Patents
Compuestos farmaceuticos derivados de piridona, pirimidona y pirazinonaInfo
- Publication number
- AR042024A1 AR042024A1 ARP030104153A ARP030104153A AR042024A1 AR 042024 A1 AR042024 A1 AR 042024A1 AR P030104153 A ARP030104153 A AR P030104153A AR P030104153 A ARP030104153 A AR P030104153A AR 042024 A1 AR042024 A1 AR 042024A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- phenyl
- optionally substituted
- alkoxy
- independently selected
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/86—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B55/00—Racemisation; Complete or partial inversion
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Transplantation (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
Abstract
Procesos para su preparación, composiciones que los contienen y su uso en terapia. Los compuestos son inhibidores de la elastasa de los neutrófilos. Reivindicación 1: Un compuesto caracterizado porque responde a la fórmula (1), donde: X representa O o S; Y1 representa N o CR2; y cuando R1 representa OH, Y1 también pude representar, en la forma tautomérica, NR6; Y2 representa CR3; y cuando Y1 representa CR2, entonces Y2 también puede representar N; R1 representa H o alquilo C1-6; donde dicho alquilo está sustituido opcionalmente con uno o más sustituyentes seleccionados en forma independiente entre halógeno, CN, CHO, OR7, NR8R9, S(O)mR10, y SO2NR11R12; y cuando Y1 representa N, R1 también puede representar OH; R7 representa H, alquilo C1-6 o fenilo; donde dicho fenilo está además sustituido opcionalmente con halógeno, alquilo C1-6 y alcoxi C1-6; R2 representa H, halógeno o alquilo C1-6; R3 representa H o F; G1 representa fenilo o un anillo heteroaromático de cinco o seis miembros que contiene entre 1 y 3 heteroátomos seleccionados en forma independiente entre O, S y N; o G1 representa un anillo cicloalquilo saturado o parcialmente insaturado de cinco o seis miembros; o G1 representa un anillo heterocíclico saturado o parcialmente insaturado de cinco o seis miembros que contiene un heteroátomo seleccionado entre O, S, y NR13 donde R13 representa H o alquilo C1-6; R5 representa H, halógeno, alquilo C1-6, CN, alcoxi C1-6, NO2, NR14R15, alquilo C1-3 sustituido con uno o más átomos de F o alcoxi C1-3 sustituido con uno o más átomos de F; R14 y R15 representan en forma independiente H o alquilo C1-3; donde dicho alquilo está además sustituido opcionalmente con uno o más átomos de F; n representa un entero seleccionado entre 1, 2 ó 3 y cuando n representa 2 o 3, cada grupo R5 se selecciona en forma independiente; R4 y R6 representan en forma independiente H o alquilo C1-6; donde dicho alquilo está además sustituido opcionalmente con OH o alcoxi C1-6; o R4 y L están unidos de manera que el grupo -NR4L representa un anillo azacíclico de 5 a 7 miembros que incorpora opcionalmente un heteroátomo adicional seleccionado entre O, S y NR16; L representa un enlace, O, NR29 o alquilo C1-6; donde dicho alquilo incorpora opcionalmente un heteroátomo seleccionado entre O, S y NR16, y donde dicho alquilo está además sustituido opcionalmente con OH o OMe; G2 representa un sistema de anillos monocíclico seleccionado entre: fenilo o fenoxi; un anillo heteroaromático de 5 ó 6 miembros que contiene entre uno y tres heteroátomos seleccionados en forma independiente entre O, S y N; un cicloalquilo C3-6 saturado o parcialmente insaturado; o un anillo heterocíclico saturado o parcialmente insaturado C4-7 que contiene uno o dos heteroátomos seleccionados en forma independiente entre O, S(O)p y NR17 y que opcionalmente incorpora además un grupo carbonilo; o G2 representa un sistema de anillos bicíclico en el cual cada uno de los dos anillos se selecciona en forma independiente entre: fenilo; un anillo heteroaromático de 5 ó 6 miembros que contiene entre uno y tres heteroátomos seleccionados en forma independiente entre O, S y N; un cicloalquilo C3-6 saturado o parcialmente insaturado; o un anillo heterocíclico saturado o parcialmente insaturado C4-7 que contiene uno o dos heteroátomos seleccionados en forma independiente entre O; S(O)p y NR17 y que opcionalmente incorpora además un grupo carbonilo; y los dos anillo están fusionados entre sí, o están unidos directamente entre sí o están separados por un grupo de enlace seleccionado entre O, S(O)q o CH2, donde dicho sistema de anillos monocíclico o bicíclico está además sustituido opcionalmente con entre uno y tres sustituyentes seleccionados en forma independiente entre CN, OH, alquilo C1-6, alcoxi C1-6, halógeno, NR18R19, NO2, OSO2R38, CO2R20, C(=NH)NH2, C(O)NR21R22, C(S)NR23R24, SC(=NH)NH2, NR31C(=NH)NH2, S(O)sR25, SO2NR26R21, alcoxi C1-3 sustituido con uno o más átomos de F y alquilo C1-3 sustituido con SO2R39 o con uno o más átomos de F; o cuando L no representa un enlace, G2 también puede representar H; m, p, q, s y t representan en forma independiente un entero seleccionado entre 0, 1 ó 2; R8 y R9 representan en forma independiente H, alquilo C1-6, formilo o alcanoilo C2-6; donde dicho alquilo está además sustituido opcionalmente con fenilo sustituido opcionalmente con halógeno, alquilo C1-6, alcoxi C1-6 o SO2R30; o el grupo NR8R9 en conjunto representa un anillo azacíclico de 5 a 7 miembros que incorpora opcionalmente un heteroátomo adicional seleccionado entre O, S y NR28; R18 y R19 representan en forma independiente H, alquilo C1-6, formilo, alcanoilo C2-6, S(O)tR32 o SO2NR33R34; donde dicho grupo alquilo está además sustituido opcionalmente con halógeno, CN, alcoxi C1-4 o CONR41R42; R25 representa H, alquilo C1-6 o cicloalquilo C3-6; donde dicho grupo alquilo está además sustituido opcionalmente con uno o más sustituyentes seleccionados en forma independiente entre OH, CN, CONR35R36, CO2R37, OCOR40; cicloalquilo C3-6, un anillo heterocíclico saturado C4-7 que contiene uno o dos heteroátomos seleccionados en forma independiente entre O, S(O)p y NR43 y fenilo o un anillo heteroaromático de 5 ó 6 miembros que contiene entre uno y tres heteroátomos seleccionados en forma independiente entre O, S y N; donde dicho anillo aromático está además sustituido opcionalmente con uno o más sustituyentes seleccionados en forma independiente entre halógeno, CN, alquilo C1-4, alcoxi C1-4, OH, CONR44R45, CO2R46, S(O)sR47 y NHCOCH3; R26 y R27 representan en forma independiente H, alquilo C1-6, formilo o alcanoilo C2-6; R32 representa H, alquilo C1-6 o cicloalquilo C3-6; R38 representa H, alquilo C1-6 o fenilo; donde dicho fenilo está además sustituido opcionalmente con halógeno, alquilo C1-6 o alcoxi C1-6; R10, R11, R12, R16, 17, R20, R21, R22, R23, R24, R28, R29, R30, R31, R33, R34, R35, R36, R37, R39, R40, R41, R42, R43, R44, R45, R46 y R47 representan en forma independiente H o alquilo C1-6; y sales aceptables para uso farmacéutico del mismo, con la condición de que se excluyen los siguientes compuestos: N-bencil-5,6-dimetil-2-oxo-1-fenil-1,2-dihidropiridin-3-carboxamida; N-(2-fenetil)-5,6-dimetil-2-oxo-1-fenil-1,2-dihidropiridin-3-carboxamida; N-(2-hidroxietil)-2,4-dioxo-3-fenil-1,2,3,4-tetrahidropirimidin-5-carboxamida; N-[2-(dimetilamino)etil]-2,4-dioxo-3-fenil-1,2,3,4-tetrahidropirimidin-5-carboxamida; ácido 4-[2-[[[1,2-dihidro-1-(4-metilciclohexil)-2-oxo-3-piridinil]carbonil]amino]etil]-benzoico; y ácido 4-[2-[[(1-ciclohexil-1,2-dihidro-2-oxo-3-piridinil)carbonil]amino]etil]-benzoico.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0203348A SE0203348D0 (sv) | 2002-11-12 | 2002-11-12 | Novel compounds |
SE0300388A SE0300388D0 (sv) | 2003-02-12 | 2003-02-12 | Novel compounds |
SE0302120A SE0302120D0 (sv) | 2003-07-22 | 2003-07-22 | Novel compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
AR042024A1 true AR042024A1 (es) | 2005-06-08 |
Family
ID=32314809
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP030104153A AR042024A1 (es) | 2002-11-12 | 2003-11-12 | Compuestos farmaceuticos derivados de piridona, pirimidona y pirazinona |
Country Status (25)
Country | Link |
---|---|
US (1) | US20060035938A1 (es) |
EP (1) | EP1562902B1 (es) |
JP (1) | JP2006513261A (es) |
KR (1) | KR20050086516A (es) |
AR (1) | AR042024A1 (es) |
AT (1) | ATE325096T1 (es) |
AU (1) | AU2003276802B2 (es) |
BR (1) | BR0316081A (es) |
CA (1) | CA2504766A1 (es) |
CY (1) | CY1106130T1 (es) |
DE (1) | DE60305061T2 (es) |
DK (1) | DK1562902T3 (es) |
ES (1) | ES2262029T3 (es) |
HK (1) | HK1079200A1 (es) |
IS (1) | IS2478B (es) |
MX (1) | MXPA05004818A (es) |
MY (1) | MY137133A (es) |
NO (1) | NO20052818L (es) |
NZ (1) | NZ539787A (es) |
PL (1) | PL376957A1 (es) |
PT (1) | PT1562902E (es) |
RU (1) | RU2328486C2 (es) |
SI (1) | SI1562902T1 (es) |
TW (1) | TW200500341A (es) |
WO (1) | WO2004043924A1 (es) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0302487D0 (sv) * | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
SE0302486D0 (sv) | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
TW200640881A (en) * | 2005-02-15 | 2006-12-01 | Du Pont | Fungicidal pyrazine derivatives |
TW200700392A (en) * | 2005-03-16 | 2007-01-01 | Astrazeneca Ab | Novel compounds |
JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
GB0605469D0 (en) * | 2006-03-17 | 2006-04-26 | Argenta Discovery Ltd | Multimers of heterocyclic compounds and their use |
TW200808763A (en) | 2006-05-08 | 2008-02-16 | Astrazeneca Ab | Novel compounds I |
TW200808771A (en) * | 2006-05-08 | 2008-02-16 | Astrazeneca Ab | Novel compounds II |
JP2009537632A (ja) * | 2006-05-19 | 2009-10-29 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | 過剰増殖性障害および血管新生障害の処置に有用なピリドンカルボキサミド誘導体 |
BRPI0711674A2 (pt) * | 2006-06-21 | 2011-11-16 | Du Pont | Método de inibição da proliferação indesejada, composto, composição e método de inibição |
WO2008053199A1 (en) * | 2006-10-30 | 2008-05-08 | Astrazeneca Ab | Combination therapy for the treatment of respiratory diseases |
WO2008107398A2 (en) * | 2007-03-02 | 2008-09-12 | Basf Se | Pyrazine compounds |
CL2008003301A1 (es) * | 2007-11-06 | 2009-10-16 | Astrazeneca Ab | Compuestos derivados de 3,4-dihidropirazina-2-carboxamida, inhibidores de la elastasa de neutrofilos humanos; composiciones farmacéuticas; procesos de preparación de compuestos y composición farmacéutica; y uso en el tratamiento de síndrome de dificultad respiratoria de los adultos, fibrosis quística, cáncer, entre otras. |
JP5216912B2 (ja) | 2008-04-29 | 2013-06-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ccr1受容体拮抗薬としてのインダゾール化合物 |
JP5411927B2 (ja) | 2008-05-06 | 2014-02-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ccr1アンタゴニストとしてのピラゾール化合物 |
NZ591115A (en) | 2008-09-26 | 2012-10-26 | Boehringer Ingelheim Int | Azaindazole compounds as ccr1 receptor antagonists |
TW201036957A (en) * | 2009-02-20 | 2010-10-16 | Astrazeneca Ab | Novel salt 628 |
WO2011039528A1 (en) * | 2009-10-02 | 2011-04-07 | Astrazeneca Ab | 2-pyridone compounds used as inhibitors of neutrophil elastase |
RS53130B (en) | 2009-10-21 | 2014-06-30 | Boehringer Ingelheim International Gmbh | INDASOL AND PYRAZOLOPYRIDINE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS |
WO2011056440A1 (en) | 2009-10-27 | 2011-05-12 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds as ccr1 receptor antagonists |
WO2011058766A1 (en) * | 2009-11-16 | 2011-05-19 | Raqualia Pharma Inc. | Aryl carboxamide derivatives as ttx-s blockers |
CN102596908A (zh) * | 2009-12-08 | 2012-07-18 | 贝林格尔.英格海姆国际有限公司 | 用于制备取代的吲唑和氮杂吲唑化合物的中间体的合成方法 |
EP2563787B1 (en) | 2010-04-30 | 2014-11-26 | Boehringer Ingelheim International GmbH | Azaindazole amide compounds as ccr1 receptor antagonists |
EP2655371B1 (en) | 2010-12-23 | 2015-02-25 | Boehringer Ingelheim International GmbH | Pyrazolopiperidine compounds as ccr1 receptor antagonists |
TWI549943B (zh) * | 2011-03-09 | 2016-09-21 | 杜邦股份有限公司 | 除草之含側氧與磺酸基(sulfono)雙氮雜環 |
CA2843836A1 (en) * | 2011-08-01 | 2013-02-07 | Dainippon Sumitomo Pharma Co., Ltd. | Uracil derivative and use thereof for medical purposes |
EP2562174A1 (de) * | 2011-08-24 | 2013-02-27 | Bayer Cropscience AG | Herbizid wirksame 6-Oxo-1,6-dihydropyrimidin-5-carboxamide und 2-Oxo-1,2-dihydropyridin-3-carboxamide |
US9206128B2 (en) | 2011-11-18 | 2015-12-08 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
EP2780013A4 (en) | 2011-11-18 | 2015-07-01 | Constellation Pharmaceuticals Inc | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF |
US9085583B2 (en) | 2012-02-10 | 2015-07-21 | Constellation—Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
US9102624B2 (en) * | 2012-08-23 | 2015-08-11 | Boehringer Ingelheim International Gmbh | Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity |
US20140057926A1 (en) | 2012-08-23 | 2014-02-27 | Boehringer Ingelheim International Gmbh | Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity |
US20140057920A1 (en) * | 2012-08-23 | 2014-02-27 | Boehringer Ingelheim International Gmbh | Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity |
JP5799117B2 (ja) * | 2013-02-05 | 2015-10-21 | 大日本住友製薬株式会社 | ウラシル誘導体からなる医薬 |
US9745305B2 (en) | 2013-03-15 | 2017-08-29 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
US9969716B2 (en) | 2013-08-15 | 2018-05-15 | Constellation Pharmaceuticals, Inc. | Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof |
US9221807B2 (en) * | 2014-02-21 | 2015-12-29 | Boehringer Ingelheim International Gmbh | Substituted pyridones and pyrazinones and their use as inhibitors of neutrophil elastase activity |
EP3174852B1 (en) * | 2014-07-30 | 2018-07-18 | Abac Therapeutics, S.L. | Arylhydrazides containing a 2-pyridone moiety as selective antibacterial agents |
WO2017040190A1 (en) | 2015-08-28 | 2017-03-09 | Constellation Pharmaceuticals, Inc. | Crystalline forms of (r)-n-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1h-indole-3-carboxamide |
US10457640B2 (en) | 2016-10-19 | 2019-10-29 | Constellation Pharmaceuticals, Inc. | Synthesis of inhibitors of EZH2 |
WO2018200571A1 (en) | 2017-04-25 | 2018-11-01 | Arbutus Biopharma Corporation | Substituted 2,3-dihydro-1h-indene analogs and methods using same |
CN111741944A (zh) | 2018-02-01 | 2020-10-02 | 悉尼大学 | 抗癌化合物 |
US11666888B2 (en) | 2018-02-05 | 2023-06-06 | Bio-Rad Laboratories, Inc. | Chromatography resin having an anionic exchange-hydrophobic mixed mode ligand |
US20220354833A1 (en) | 2019-09-17 | 2022-11-10 | Mereo Biopharma 4 Limited | Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease |
IL297211A (en) | 2020-04-16 | 2022-12-01 | Mereo Biopharma 4 Ltd | Methods involving the neutrophil elastase inhibitor albalstat for the treatment of respiratory disease mediated by alpha-1 antitrypsin deficiency |
CA3234399A1 (en) | 2021-10-20 | 2023-04-27 | Mereo Biopharma 4 Limited | Neutrophil elastase inhibitors for use in the treatment of fibrosis |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US541960A (en) * | 1895-07-02 | Nose-piece for eyeglasses | ||
DE2706977A1 (de) * | 1977-02-18 | 1978-08-24 | Hoechst Ag | Benzoesaeuren und deren derivate sowie verfahren zu ihrer herstellung |
US4816658A (en) * | 1983-01-10 | 1989-03-28 | Casi-Rusco, Inc. | Card reader for security system |
US5420297A (en) * | 1990-10-24 | 1995-05-30 | Fujisawa Pharmaceutical Co., Ltd. | Peptides having substance P antagonistic activity |
GB9207145D0 (en) * | 1991-04-18 | 1992-05-13 | Ici Plc | Heterocyclic amides |
GB9216272D0 (en) * | 1991-08-15 | 1992-09-09 | Ici Plc | Substituted heterocycles |
US5441960A (en) * | 1992-04-16 | 1995-08-15 | Zeneca Limited | 1-pyrimidinylacetamide human leukocyte elastate inhibitors |
CA2421499A1 (en) * | 2000-09-08 | 2003-03-06 | Ono Pharmaceutical Co., Ltd. | Novel crystals of 1,3,4-oxadiazole derivative, process for producing the same and pharmaceutical agent containing the same as active ingredient |
KR100828982B1 (ko) * | 2000-12-28 | 2008-05-14 | 시오노기세이야쿠가부시키가이샤 | 칸나비노이드 2형 수용체 친화 작용을 갖는 피리돈 유도체 |
GB0129260D0 (en) * | 2001-12-06 | 2002-01-23 | Eisai London Res Lab Ltd | Pharmaceutical compositions and their uses |
US20050076782A1 (en) * | 2001-12-21 | 2005-04-14 | Weinbren Milton Lawrence | Gas scrubber |
SE0302324D0 (sv) * | 2003-08-28 | 2003-08-28 | Astrazeneca Ab | Novel compounds |
SE0302323D0 (sv) * | 2003-08-28 | 2003-08-28 | Astrazeneca Ab | Novel compounds |
SE0302486D0 (sv) * | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
SE0302487D0 (sv) * | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
-
2003
- 2003-11-06 TW TW092131093A patent/TW200500341A/zh unknown
- 2003-11-10 MY MYPI20034290A patent/MY137133A/en unknown
- 2003-11-11 DK DK03811170T patent/DK1562902T3/da active
- 2003-11-11 ES ES03811170T patent/ES2262029T3/es not_active Expired - Lifetime
- 2003-11-11 BR BR0316081-5A patent/BR0316081A/pt not_active IP Right Cessation
- 2003-11-11 CA CA002504766A patent/CA2504766A1/en not_active Abandoned
- 2003-11-11 DE DE60305061T patent/DE60305061T2/de not_active Expired - Fee Related
- 2003-11-11 RU RU2005113168/04A patent/RU2328486C2/ru not_active IP Right Cessation
- 2003-11-11 PT PT03811170T patent/PT1562902E/pt unknown
- 2003-11-11 WO PCT/SE2003/001739 patent/WO2004043924A1/en active IP Right Grant
- 2003-11-11 PL PL376957A patent/PL376957A1/pl not_active Application Discontinuation
- 2003-11-11 AU AU2003276802A patent/AU2003276802B2/en not_active Ceased
- 2003-11-11 US US10/534,720 patent/US20060035938A1/en not_active Abandoned
- 2003-11-11 MX MXPA05004818A patent/MXPA05004818A/es active IP Right Grant
- 2003-11-11 JP JP2005506687A patent/JP2006513261A/ja active Pending
- 2003-11-11 SI SI200330314T patent/SI1562902T1/sl unknown
- 2003-11-11 NZ NZ539787A patent/NZ539787A/en unknown
- 2003-11-11 AT AT03811170T patent/ATE325096T1/de not_active IP Right Cessation
- 2003-11-11 KR KR1020057008383A patent/KR20050086516A/ko not_active Application Discontinuation
- 2003-11-11 EP EP03811170A patent/EP1562902B1/en not_active Expired - Lifetime
- 2003-11-12 AR ARP030104153A patent/AR042024A1/es unknown
-
2005
- 2005-05-26 IS IS7867A patent/IS2478B/is unknown
- 2005-06-10 NO NO20052818A patent/NO20052818L/no not_active Application Discontinuation
- 2005-12-06 HK HK05111156A patent/HK1079200A1/xx not_active IP Right Cessation
-
2006
- 2006-07-27 CY CY20061101039T patent/CY1106130T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
SI1562902T1 (sl) | 2006-08-31 |
AU2003276802A1 (en) | 2004-06-03 |
DE60305061D1 (de) | 2006-06-08 |
JP2006513261A (ja) | 2006-04-20 |
EP1562902A1 (en) | 2005-08-17 |
NO20052818L (no) | 2005-07-11 |
PL376957A1 (pl) | 2006-01-09 |
IS2478B (is) | 2008-12-15 |
WO2004043924A1 (en) | 2004-05-27 |
TW200500341A (en) | 2005-01-01 |
ATE325096T1 (de) | 2006-06-15 |
NZ539787A (en) | 2006-11-30 |
US20060035938A1 (en) | 2006-02-16 |
AU2003276802B2 (en) | 2007-03-08 |
CY1106130T1 (el) | 2011-06-08 |
ES2262029T3 (es) | 2006-11-16 |
KR20050086516A (ko) | 2005-08-30 |
BR0316081A (pt) | 2005-09-27 |
DE60305061T2 (de) | 2006-12-07 |
EP1562902B1 (en) | 2006-05-03 |
DK1562902T3 (da) | 2006-08-14 |
MY137133A (en) | 2008-12-31 |
RU2005113168A (ru) | 2006-01-20 |
MXPA05004818A (es) | 2005-07-22 |
PT1562902E (pt) | 2006-08-31 |
RU2328486C2 (ru) | 2008-07-10 |
IS7867A (is) | 2005-05-26 |
HK1079200A1 (en) | 2006-03-31 |
CA2504766A1 (en) | 2004-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR042024A1 (es) | Compuestos farmaceuticos derivados de piridona, pirimidona y pirazinona | |
AR045761A1 (es) | Derivados de 2-piridona como inhibidores de elastasa de neutrofilos | |
AR060875A1 (es) | Derivados de 2-piridona como inhibidores de la neutrofilo elastasa humana | |
AR046083A1 (es) | Derivados de 2 piridona como inhibidores de la elastasa de neutrofilos | |
PE20070218A1 (es) | COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA | |
AR044614A1 (es) | Composiciones de sulfonamida que modulan la actividad del receptor de quinioquinas (ccr4) | |
AR069543A1 (es) | Derivados bis-(sulfonilamino), composiciones farmaceuticas que los contienen y su uso en terapia. | |
AR046244A1 (es) | Activadores de glucoquinasa heteroaromaticos de seis miembros 5- sustituidos | |
AR049739A1 (es) | Derivados de aril-piridina | |
PE20080404A1 (es) | Derivados bencil-amino-piperidina como inhibidores de cetp | |
AR061844A1 (es) | Pirimidil-ciclopentanos como inhibidores de protein-quinasa akt | |
HRP20090151T3 (en) | Indozolone derivatives as 11b-hsd1 inhibitors | |
AR053405A1 (es) | Derivados de urea sustituidas, composiciones farmaceuticas y metodos para el tratamiento de cardiopatias | |
NZ610312A (en) | 6-amino-2-phenylamino-1h-benzimidazole-5-carboxamide- derivatives and their use as microsomal prostaglandin e2 synthase-1 inhibitors | |
PE20030703A1 (es) | Inhibidores de la 17b-hidroxiesteroide deshidrogenasa tipo 3 | |
AR036659A1 (es) | Compuestos derivados de fenil-piperazina, fenil-piperidina y fenil-tetrahidropiridina como inhibidores de la reabsorcion de la serotonina, una composicion farmaceutica y utilizacion de los mismos para la preparacion de medicamentos | |
NO20062193L (no) | Bisykliske [3.1.0] derivater som glysintransportorinhibitorer | |
AR053652A1 (es) | Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas | |
PE20120635A1 (es) | Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas | |
BRPI0511186A (pt) | composto, pró-droga do composto, composição farmacêutica, uso do composto, e, processo para preparar o composto | |
PE20141075A1 (es) | 4-aril-n-fenil-1,3,5-triazin-2-aminas que contienen un grupo sulfoximina | |
AR041260A1 (es) | Piperazinas sustituidas por heterociclos para el tratamiento de la esquizofrenia | |
PE20040155A1 (es) | Derivados aminoinazoles, procedimiento de preparacion e intermedios de este procedimiento a titulo de medicamentos y composiciones farmaceuticas que los contienen | |
PE20090509A1 (es) | El uso de derivados de benzamida para el tratamiento de transtornos del snc | |
AR066669A1 (es) | Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |